St. Jude Children’s Research Hospital® will celebrate its 14th annual FedEx/St. Jude Angels and Stars Gala, by welcoming back model and television personality, as well as co-founder, Daisy Fuentes, for an evening of fine dining and Latin music at 6:30 p.m. on Saturday, May 14, at the Intercontinental Hotel in downtown Miami. The annual event raises funds to help ensure families never receive a bill from St. Jude for treatment, travel, housing or food – because all a family should worry about is helping their child live.
Cuban-born American journalist and one of Time magazine’s “25 Most Influential Hispanics in America,” Cristina Saralegui, will be recognized for her commitment to giving back and educating the Hispanic community. “Being recognized by St. Jude Children’s Research Hospital is a true honor. Lending my voice to matters that touch my heart is what’s it’s all about. These children need our help and they need your help,” said Saralegui.
To view the multimedia release go to:
http://www.multivu.com/players/English/7758751-st-jude-angels-stars-gala/
Miral and SeaWorld Entertainment, Inc. (NYSE:SEAS) (“SeaWorld”) today announced their partnership to develop SeaWorld Abu Dhabi, a first-of-its-kind marine life themed park on Yas Island. This next generation SeaWorld Abu Dhabi will also include the United Arab Emirates’ (“UAE”) first dedicated marine life research, rescue, rehabilitation and return center with world-class facilities and resources for the care and conservation of local marine life. SeaWorld Abu Dhabi will be the first new SeaWorld without orcas, and will integrate up-close animal experiences, mega attractions and a world class aquarium, bringing the latest technology in visitor engagement.
The partnership brings together Miral’s expertise in developing Yas Island’s portfolio of destinations with SeaWorld’s 50-plus years of theme park, veterinary medicine, marine science and zoological practice and experience.
To view the multimedia release go to:
http://www.multivu.com/players/uk/8002251-miral-announces-seaworld-yas-island/
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
Nestlé Purina, a global leader in pet care, hosted its fourth annual Better with Pets Summit at the Brooklyn Expo Center in New York City on Tuesday, October 18, bringing together pet community experts and leaders across the nation to explore how pets and people are living bigger and better lives thanks to new research and innovation that will shape the future of pet care.
Featuring three interactive panel discussions, the Better with Pets Summit examined topics that continue to affect pet care and wellness including the evolving role of pets and their impact on people’s well-being, nutritional innovation that will allow pets to live healthier lives, and demystifying pet nutrition quality and safety standards.
To view the multimedia release go to:
http://www.multivu.com/players/English/7923051-purina-better-with-pets-2016-summit/
Blood cancers are the third leading cause of cancer deaths in the U.S. However, many Americans are unaware of the impact of these cancers, including leukemia, lymphoma and myeloma, which affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system.
A new survey commissioned by The Leukemia & Lymphoma Society (LLS) reveals more than four in five adults (82%) are surprised that blood cancers are the third leading cancer killer of Americans. Further, nearly four in five adults (78%) are surprised that acute lymphocytic leukemia (ALL) is the most common cancer in children and young adults under age 20.
To view the multimedia release go to:
https://www.multivu.com/players/English/8128551-lls-blood-cancer-awareness-month/
The TOEIC Program recently launched Why English Matters, a new content-based website that seeks to build awareness and share information about the important role that English-language proficiency plays in the global economy.
Why English Matters features a new video documentary series that explores the role of English through interviews with human resource managers and decision makers from leading global organizations. The site also features related research and news articles about the impact of effective English communication skills for the international workforce.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7056051-ets-toeic-program-why-english-matters-website-documentary-series
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Pro-ducts for Human Use (CHMP) recommended that the European Commission approve the use of Xadago™ (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ‘Standard of Care’.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons/
NFL PLAY 60, the National Football League’s youth health and fitness campaign, is the new “Official Champion of Play” at St. Jude Children’s Research Hospital®, the global leader in finding cures and saving children with cancer and other deadly diseases.
To commemorate this new milestone in the ongoing partnership between the NFL and St. Jude, a St. Jude patient will join NFL commissioner Roger Goodell on stage to announce a pick during the first round of the 2013 NFL Draft. The NFL Network and ESPN will televise live coverage of the NFL Draft beginning at 8 p.m. EST on Thursday, April 25.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58566-st-jude-children-s-research-hospital-nfl-play-60
Today, the American Immigration Lawyers Association (AILA) issued a report card on President Obama's immigration efforts over the past seven years and made recommendations for how to reform immigration in his last year.
“In recent days and weeks he has shown leadership in protecting refugees from Syria,” said AILA President Victor Nieblas Pradis. “But until recently, the president's response was timid and he still plans to resettle only 10,000 Syrian refugees this year. He can save many more lives by setting his target at 100,000 Syrian refugees.”
“In our own hemisphere, when Central American individuals and families, including young children, arrived at our southern border seeking refuge from the horrific violence plaguing those countries, the president should have protected them, but instead, he treated them as a border threat. The president should acknowledge that the situation in Central America is a humanitarian crisis and use every tool at his disposal to protect those fleeing. Most important he should stop detaining thousands of families.”
“The reforms to the legal immigration system he promised a year ago have moved forward at a glacial pace, earning him an incomplete. He can benefit the economy enormously by implementing plans to encourage research, development and entrepreneurial start-ups.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7683151-aila-national-immigration-report-card/
Do science and religion conflict? Is there disagreement between science and spirituality? It turns out there is no conflict. The apparent conflict is because, till now, the metaphors of ancient texts such as the Bible, Talmud, and ancient Yoga Literature, had not been rigorously studied and compared to cutting edge scientific discoveries. Some of these studies have been reviewed by scientists and published in three international peer-reviewed scientific journals. Sanjay's research on the new agreements between spirituality and science is the first ever to get published in such high-ranking journals.
By Sanjay C. Patel, Author of GOD IS REAL - The Stunning New Convergence of Science and Spirituality. Visit: http://www.SanjayCPatel.com
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
